Generic
Lurbinectedin
1 brands available in the market
At a glance
Lurbinectedin is used for the treatment of metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.
Description
Lurbinectedin is an alkylating drug that binds to guanine residues in the minor groove of DNA, forming adducts and causing bending of the DNA helix. Adduct formation triggers a cascade of events affecting DNA binding proteins and DNA repair pathways, resulting in cell cycle perturbation and eventual cell death.
Indications
- Metastatic small cell lung cancer (SCLC) - disease progression on or after platinum-based chemotherapy (accelerated approval)
Therapeutic class
Cytotoxic Chemotherapy
Pharmacological class
Alkylating Agent
Pharmacology
Lurbinectedin binds to guanine in the minor groove of DNA to form adducts, disrupting DNA binding protein activity and DNA repair pathways, leading to cell cycle disruption and cell death.
Mechanism of action
Forms DNA adducts to disrupt cell division and destroy cancer cells.
Dosage
Adult Dose (IV):
- 3.2 mg/m² IV infusion over 60 minutes every 21 days
- Continue until disease progression or unacceptable toxicity
- Initiate only if ANC ≥1,500 cells/mm³ and platelets ≥100,000/mm³
Administration
- IV infusion over 60 minutes
- Repeat every 21 days
- Consider central venous catheter to reduce risk of extravasation
Missed dose
Not generally applicable (professionally administered); consult doctor if needed.
Side effects
Common Side Effects (≥20%):
- Leukopenia, lymphopenia, neutropenia, thrombocytopenia
- Fatigue, anemia
- Increased creatinine, ALT, AST, glucose; decreased sodium, magnesium
- Nausea, vomiting, diarrhea, constipation
- Decreased appetite, musculoskeletal pain, dyspnea, cough
Precautions & warnings
- Myelosuppression: Monitor blood counts prior to each administration
- Hepatotoxicity: Monitor liver function tests before and during treatment
- Extravasation: Can cause tissue necrosis; monitor during infusion
- Rhabdomyolysis: Monitor CPK
- Embryo-fetal toxicity: Use effective contraception
Contraindications
- Hypersensitivity to Lurbinectedin or its components
Drug interactions
No significant drug interactions known.
Food interactions
No food interactions applicable (IV administration).
Use in pregnancy
Use in Pregnancy: Can cause fetal harm when administered to a pregnant woman; no data on use in pregnancy.
Use in lactation
Use in Lactation: No data on presence in human milk; due to potential for serious adverse reactions, do not breastfeed during treatment and for 2 weeks after the last dose.
Pediatric use
Safety and efficacy not established in pediatric patients.
Geriatric use
No special dose adjustment needed in elderly.
Renal / hepatic impairment
No specific dose adjustment information available for renal or hepatic impairment.
Overdose effects
No specific overdose information available; symptomatic and supportive measures should be employed.
Storage conditions
Store below 30°C, away from light and moisture; keep out of reach of children.
Chemical structure
Lurbinectedin